Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Summit Therapeutics (SMMT) Stock Price & Analysis
276 Followers
SMMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $5.22
Previous Close$4.14
Volume4.68M
Average Volume (3M)2.35M
Market Cap
$2.91B
Enterprise Value$2.82B
Total Cash (Recent Filing)$186.24M
Total Debt (Recent Filing)$106.10M
Price to Earnings (P/E)-2.7
Beta-1.56
Next Earnings
May 09, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding701,697,179
10 Day Avg. Volume3,553,703
30 Day Avg. Volume2,353,294
Standard Deviation0.61
R-Squared0.01
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)34.72
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.84K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.97
Forecast
1Y Price Target
$8.00Price Target Upside93.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Summit Therapeutics News
PremiumCompany Announcements
Summit Therapeutics Appoints Biotech Veteran to Board
PremiumCompany Announcements
Summit Therapeutics Announces Major Leadership Restructuring
Ownership Overview
82.82% Insiders
1.50% Mutual Funds
3.16% Other Institutional Investors
12.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $1.30 and its highest was $5.22 in the past 12 months.
What is Summit Therapeutics’s market cap?
Currently, no data Available
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 23 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Feb 20, 2024. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 701,697,200 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26.233%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Among the largest hedge funds holding Summit Therapeutics’s share is Robert Bender&Associates. It holds Summit Therapeutics’s shares valued at 63K.
---
Summit Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (93.24% Upside)
$8.00 (93.24% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $786.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.57%
12-Months-Change
Fundamentals
Return on Equity
-601.88%
Trailing 12-Months
Asset Growth
-69.44%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
---
SMMT Earnings Call
Q4 2024
0:00 / 0:00
---
SMMT Stock 12 Months Forecast
Average Price Target
$8.00
▲(93.24% Upside)
Technical Analysis
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+10.60%
initiated a buy rating 22 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +10.60% per trade.
---